Please login to the form below

Not currently logged in
Email:
Password:

Biktarvy

This page shows the latest Biktarvy news and features for those working in and with pharma, biotech and healthcare.

ViiV builds case for switching to its two-drug HIV combinations

ViiV builds case for switching to its two-drug HIV combinations

Taking aim at rival Biktarvy. ViiV Healthcare says it has data that shows people with HIV can safely switch from Gilead's three-drug therapies to one of its two-drug ... For comparison, Biktarvy brought in $739m in sales in the first quarter of the year,

Latest news

More from news
Approximately 4 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics